Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1
Recruiting
- Conditions
- HER2 Mutation-Related TumorsHER2HER2-positive Breast CancerHER2 + Breast CancerBrain Metastases from Solid TumorsBrain Metastases from HER2 and Breast CancerCNS MetastasesHER2-Positive Solid TumorsNSCLC (non-small Cell Lung Cancer)HER2-positive Bladder Cancer
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Iambic Therapeutics, Inc
- Target Recruit Count
- 243
- Registration Number
- NCT06253871
- Locations
- 🇺🇸
Comprehensive Hematology Oncology, Saint Petersburg, Florida, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
News
No news found